SPX3,978.73+37.25 0.95%
DIA321.28+1.89 0.59%
IXIC11,434.74+170.29 1.51%

BRIEF-Rezolute Announces Positive Data From Phase 2B Study Of RZ358 In Patients With Congenital Hyperinsulinism

reuters.com · 05/01/2022 14:02
BRIEF-Rezolute Announces Positive Data From Phase 2B Study Of RZ358 In Patients With Congenital Hyperinsulinism

- Rezolute Inc RZLT:

  • REZOLUTE ANNOUNCES POSITIVE DATA FROM ITS PHASE 2B (RIZE) STUDY OF RZ358 IN PATIENTS WITH CONGENITAL HYPERINSULINISM

  • HIGHLY SIGNIFICANT ABOUT 75% REDUCTION IN HYPOGLYCEMIA EVENTS AT ANTICIPATED THERAPEUTIC DOSES

  • REZOLUTE- ≥50% IMPROVEMENT IN HYPOGLYCEMIA IN 100% OF PATIENTS IN HIGH-DOSE COHORT, NO ADVERSE DRUG REACTIONS OR CLINICALLY SIGNIFICANT HYPERGLYCEMIA

Source text for Eikon: ID:nGNXbV0QQL

Further company coverage: RZLT


((Reuters.Briefs@thomsonreuters.com;))